CLICK TO READ ENTIRE TRANSCRIPT With the reach and impact of biopharma growing exponentially, experts in biotech and the evolving regulatory environment came …
Stories
Akari on the Business of Biotech podcast
Ticks aren’t all bad! Check out the Business of Biotech podcast to hear how Akari engineered #nomacopan, a recombinant protein derived from ticks, and scaled …
[Read more...] about Akari on the Business of Biotech podcast
Rich Database Underpins Predictive PK/PD Model
Akari clinical data from 38 subjects (in previous clinical studies and healthy volunteers) support robust PK/PD model simulations used to select doses for …
[Read more...] about Rich Database Underpins Predictive PK/PD Model
Simulated 10,000 Virtual Patients
Akari's robust PK/PD model simulated 10,000 virtual patients informing U.S. FDA MIDD interactions that helped confirm PK/PD model suitability & doses …
Thrombotic Microangiopathy
Thrombotic microangiopathy following a stem cell transplant is a rare but serious complication that often leads to progressive organ damage and death. Akari is …
